Latest News

COVID-19 study incorporating Dimerix's DMX-200 adds more sites August 3, 2021

Dimerix (ASX:DXB) has announced that 167 patients have now been recruited into the feasibility/Phase 3 ACE2 renin-angiotensin system modulation study domain in patients with COVID-19 pneumonia that incorporates DMX-200.

Bionomics announces plans for US initial public offering August 3, 2021

Bionomics (ASX:BNO) has announced that it plans to conduct a registered initial public offering of shares in the US and a listing on Nasdaq.

Faecal transplants to help treat symptoms of Parkinson’s August 3, 2021

Faecal transplants are the latest new treatment option being trialled in people living with Parkinson’s to help manage their symptoms by replenishing their healthy gut bacteria.

Glyscend Therapeutics commences clinical trial of potential diabetes treatment August 3, 2021

A potential new oral treatment for type 2 diabetes therapy will commence recruitment for a Phase I clinical trial in South Australia following promising preclinical study results.

AusBiotech 2021 programme released August 3, 2021

The AusBiotech 2021 programme has been released, and features global thought-leaders, and pressing and emerging topics to drive the Australian biotech sector forward.

Antisense Therapeutics announces transition to new board chair July 29, 2021

Antisense Therapeutics (ASX:ANP) has announced that non-executive director Dr Charmaine Gittleson will transition to succeed Bob Moses as the chair of its board.

Chimeric Therapeutics licenses CAR-T therapy from the University of Pennsylvania July 29, 2021

Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has entered into an exclusive licensing agreement with the University of Pennsylvania for the CDH17 chimeric antigen receptor T cell therapy.

Carina Biotech announces the members of its new medical advisory board July 29, 2021

Carina Biotech has announced the four members of its new medical advisory board that will support the company to take its LGR5-targeted CAR-T cell for advanced colorectal cancer into the clinic.

Draft roadmap for Australian regenerative medicine released for comment July 29, 2021

A draft strategic roadmap has been released for a new regenerative medicine (RM) Catalyst, and sector feedback is sought from those interested in the future of RM in Australia.

AROA Biosurgery completes significant capital raise July 29, 2021

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) has announced the successful completion of a $47 million placement to institutional and sophisticated investors.

Hexima announces the completion of enrolment in phase IIb clinical trial July 27, 2021

Clinical stage biotechnology company Hexima (ASX:HXL) says it has completed the enrolment of patients in its phase IIb clinical trial evaluating pezadeftide (HXP124) as a potential new topical treatment for onychomycosis.

Patrys announces preclinical data for PAT-DX1 in pancreatic cancer July 27, 2021

Patrys (ASX:PAB) says new preclinical data from the Garvan Institute of Medical Research has shown that its’ deoxymab antibody PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer.

Most Read

Faecal transplants to help treat symptoms of Parkinson’s

AusBiotech 2021 programme released

Bionomics announces plans for US initial public offering

Glyscend Therapeutics commences clinical trial of potential diabetes treatment

COVID-19 study incorporating Dimerix's DMX-200 adds more sites

New Stories

COVID-19 study incorporating Dimerix's DMX-200 adds more sites

Bionomics announces plans for US initial public offering

Faecal transplants to help treat symptoms of Parkinson’s

Glyscend Therapeutics commences clinical trial of potential diabetes treatment

AusBiotech 2021 programme released

Antisense Therapeutics announces transition to new board chair

Chimeric Therapeutics licenses CAR-T therapy from the University of Pennsylvania

Sign In

Most Read

Faecal transplants to help treat symptoms of Parkinson’s

AusBiotech 2021 programme released

Bionomics announces plans for US initial public offering

Glyscend Therapeutics commences clinical trial of potential diabetes treatment

COVID-19 study incorporating Dimerix's DMX-200 adds more sites

Follow Us

New Stories

COVID-19 study incorporating Dimerix's DMX-200 adds more sites

Bionomics announces plans for US initial public offering

Faecal transplants to help treat symptoms of Parkinson’s

Glyscend Therapeutics commences clinical trial of potential diabetes treatment

AusBiotech 2021 programme released

Antisense Therapeutics announces transition to new board chair

Chimeric Therapeutics licenses CAR-T therapy from the University of Pennsylvania